The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
News|Articles|May 2, 2025
FDA News Recap: April 2025
Author(s)Victoria Johnson
Fact checked by: Connor Iapoce
Key Takeaways
- Atrasentan, inebilizumab, and maralixibat received FDA approval, highlighting advancements in IgA nephropathy, IgG4-related disease, and cholestatic pruritus treatment.
- Label expansions for osilodrostat and mavacamten provided new therapeutic options for pediatric Cushing's syndrome and obstructive hypertrophic cardiomyopathy.
This FDA News Month in Review provides a round-up of regulatory decisions from April 2025.
Advertisement
Advertisement
Related to this article
Amgen reported dazodalibep met its primary endpoint in the phase 3 OASIZ-301 trial, improving ESSDAI score in moderate-to-severe systemic Sjögren's disease.
Rozanolixizumab improved FIQR score at 10 weeks but did not reach 2-sided statistical significance on its primary BPI-SF interference endpoint.
Two-year data from the open-label extension show sustained ACR and MDA response rates for the TYK2 inhibitor in active psoriatic arthritis.
Oberlin outlines what dermatologists should weigh, beyond APEX's radiographic data, when selecting a biologic for PsA.
Beeline Medicines reported positive topline data meeting primary SRI-4 endpoint at week 48 across all 3 doses in systemic lupus erythematosus.
The designation follows phase 2 IMPACT trial data showing reduced adverse pregnancy outcomes in high-risk antiphospholipid syndrome.
In a large real-world PsA cohort, higher BMI reduced the odds of minimal disease activity, especially with TNF inhibitors other than infliximab.
Advertisement
Advertisement